TY  - JOUR
T1  - POor benefit/risk balance of intravenous immunoglobulins in dress
AU  - Joly P, Janela B, Tetart F, et al
Y1  - 2012/04/01
N1  - 10.1001/archderm.148.4.dlt120002-c
JO  - Archives of Dermatology
SP  - 543
EP  - 544
VL  - 148
IS  - 4
N2  - 
Drug reaction with eosinophilia and systemic symptoms (DRESS), sometimes called hypersensitivity syndrome, is a severe drug-induced reaction with visceral involvement and blood abnormalities associated with reactivations of viruses of the herpes family: human herpesvirus (HHV)-6 HHV-7, Epstein-Barr virus (EBV), and cytomegalovirus (CMV).1 Our research group2 recently reported that the immune response in DRESS, previously thought to be directed against drug components, is in fact mediated by tumor necrosis factor (TNF)–and interferon-γ (INF-γ)–secreting CD8+ T lymphocytes, which are directed against previously quiescent HHVs reactivated by the drug and home to the skin and visceral organs.2 Oral corticosteroid treatment is often proposed for severe DRESS, but oral corticosteroids might favor a relapsing course of the syndrome. Some researchers,3- 4 based on the presence of antiviral IgGs in intravenous immunoglobulins (IVIGs) and their numerous immunologic effects, have suggested that IVIGs might be effective in a few patients with DRESS, although these patients were concomitantly treated with systemic corticosteroids. The aim of the present study was to evaluate the safety and efficacy of IVIGs in patients with DRESS and to assess the evolution of immunologic and virologic parameters after treatment.

SN  - 0003-987X
M3  - doi: 10.1001/archderm.148.4.dlt120002-c
UR  - http://dx.doi.org/10.1001/archderm.148.4.dlt120002-c
ER  -